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Comparison of tube and gel red
blood cell agglutination techniques
in detecting chimeras after major
ABO-mismatched allogeneic
hematopoietic stem cell 
transplantation
M.J. KUPFERMAN, K.M. CIPOLONE, J.L. PROCTER,AND D.F. STRONCEK
We compared the ability of tube and gel red blood cell (RBC) agglu-
tination techniques to follow erythroid engraftment in a patient who
received a major ABO-mismatched peripheral blood stem cell trans-
plant and bone marrow transplant. Tube and gel RBC agglutination
techniques were used to detect mixed-field reactivity in cell mixtures
containing A/O and c+/c– RBCs and the ability of these two tech-
nologies to detect RBC chimeras were compared. We detected c+
RBCs in c+/c– RBC populations microscopically at 1% by the tube
RBC agglutination technique, but not until 10% by the gel technique.
Group A RBCs in A/O RBC populations were detected at 10% by both
techniques. In the patient studied, group A RBCs and c+ RBCs were
detected on Days 20 and 14, respectively, with the tube RBC agglu-
tination technique, but neither marker was detected until Day 26
with the gel technique. Tube and gel RBC agglutination techniques
comparably identified ABO mixed fields. Although the tube RBC
agglutination technique showed greater sensitivity than the gel tech-
nique in detecting the c antigen, the gel technique was easier to use
and allowed more reliable interpretation of mixed fields by the tech-
nologist. Immunohematology 1998;14:63–67.
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Patients with hematologic malignancies who undergo
ablative therapy involving total-body irradiation and
cytotoxic drugs are often rescued from such treatment
with a transplantation of allogeneic stem cells from bone
marrow. Collecting the donor’s bone marrow, however,
is a painful procedure usually requiring hospitalization
and general anesthesia.1 This process now can be avoid-
ed because of the efficacy of a synthetic preparation of
the growth factor, granulocyte colony–stimulating factor
(G-CSF), in increasing the number of stem cells in the
peripheral circulation.2 Peripheral blood stem cells
(PBSCs) are an easily accessible alternative to bone mar-
row as a source of stem cells for transplantation in treat-
ing hematologic malignancies. Recent studies indicate
that by optimizing stem cell and lymphocyte doses, an
allogeneic PBSC transplantation performed in place of
an allogeneic bone marrow transplant (BMT) results in
faster engraftment, fewer posttransplant red blood cell
(RBC) and platelet transfusions,and no greater incidence
of acute or chronic graft-versus-host disease (GVHD).3
Thus, transplant outcome can be improved.
Regardless of matched donor-recipient pair ABO
types, PBSCs from HLA-identical sibling donors have
been used to treat patients with severe hematologic
malignancies including chronic myelogenous leukemia
(CML), acute lymphoblastic leukemia, and multiple
myeloma. In fact, 15 percent to 20 percent of allogeneic
BMT cases involve ABO-incompatible transplants,4 and
studies indicate that ABO incompatibility does not affect
the incidence of graft rejection,4 engraftment,5 GVHD,6
or patient survival in BMT.7
This study compared the ability of tube and gel RBC
agglutination techniques to follow erythroid engraft-
ment. We compared their efficacy in detecting antigen
markers in prepared mixtures of RBC populations and in
mixtures resulting from in vivo engraftment of erythroid
cells. A 37-year-old male patient with CML received
major ABO-mismatched PBSCs as well as bone marrow
from an HLA-identical sibling.Because the donor and the
recipient were mismatched in both the ABO and c phe-
notypes, it was possible to analyze the sensitivity of the
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traditional tube RBC agglutination technique and the gel
RBC agglutination technique in detecting mixed 
chimerism as RBC engraftment occurred in the weeks
following transplantation.
Case Report
Serologic and historical data were collected on a 37-
year-old male patient with CML who was treated by
hematopoietic stem cell transplantation. The patient,
group O, c–, received major ABO-mismatched PBSC and
bone marrow transplants from a 58-year-old, HLA-
matched group A, c+ sister.
The PBSC donor was given six doses of G-CSF on each
of the 6 days before the transplant to increase the stem
cells (identified by a CD34+ marker) in her peripheral
circulation from normal levels of less than 2 × 106
CD34+ cells per liter to 16 × 106 CD34+ cells per liter.
The PBSC collection was performed by apheresis on
both the day before transplant (Day –1) and the day of
the transplant (Day 0). The collected products were
pooled on Day 0.
To isolate CD34+ stem cells from the pooled product,
biotinylated anti-CD34 was used. The treated product
was then run through a column containing avidin
(CellPro, Inc., Bothell,WA), from which the CD34+ rich
product was removed and collected in a bag.The PBSC
product then underwent a negative selection procedure
using biotinylated anti-CD2 and a second avidin column
(CellPro, Inc.). Because T-lymphocytes are implicated in
acute GVHD, the goal of the negative selection was to
reduce their number to levels below 1 × 105 CD3+ cells
per kilogram of the patient’s weight. After processing,
the PBSC product contained 1.63 × 106 CD34+ cells per
kilogram of the patient’s weight and 0.26 × 105 CD3+
cells per kilogram of the patient’s weight.
Because the minimum transplant dose established by
the transplant protocol was 3 × 106 CD34+ cells per kilo-
gram of the patient’s weight, additional donor stem cells
were collected by bone marrow aspiration on Day 1.The
marrow was processed only to select for CD34+ cells, as
described for the PBSC product (CellPro, Inc.).After pro-
cessing, the bone marrow product contained 1.06 × 106
CD34+ cells per kilogram of the patient’s weight and
0.25 × 106 CD3+ cells per kilogram of the patient’s
weight.
The patient was given a preparative regimen of 1,360
rads of TBI given in eight doses on pretransplant Day –7
through Day –4 and 60 mg/kg doses of cyclophos-
phamide on pretransplant Day –3 and Day –2. He was
then transfused with the PBSCs on Day 0 and additional
marrow on Day 1, for a total of 2.69 × 106 CD34+ cells
and 0.5 × 105 CD3+ cells.
Materials and Methods
To establish the baseline sensitivities of the tube and
gel RBC agglutination techniques in detecting mixed
chimeras, an initial analysis was performed with RBC
mixtures prepared in the laboratory. Six chimeric sam-
ples were created by mixing the appropriate volumes of
group A, c+ RBCs with group O, c– RBCs, such that the
concentration of the group A, c+ population sequential-
ly increased from 1 percent to 50 percent. Cell mixtures
of 1, 10, 20, 30, 40, and 50 percent were prepared. Each
mixture was then typed simultaneously by both the tube
and gel RBC agglutination techniques (Micro Typing
Systems, Inc., Pompano Beach, FL).8
Samples of the PBSC transplant recipient’s RBCs and
plasma were collected in EDTA tubes and tested on Days
8, 14, 20, 26, 34, and 42.To detect mixed chimeras, each
sample was typed for ABO and c by both the gel and the
traditional tube RBC agglutination techniques using
mouse monoclonal antisera. Standard methods were fol-
lowed to perform isohemagglutinin titrations and direct
antiglobulin tests (DATs) on samples collected from the
patient.8 When the DAT was positive, antibody specifici-
ty was determined by performing a rapid acid elution
from intact RBCs according to the manufacturer’s direc-
tions (Elu-Kit II, Gamma Biologicals, Inc., Houston,TX).
All agglutination reactions were graded as indicated in
Table 1.8 All testing was performed by one person.
Results
Analysis of in vitro mixed chimeras
The tube RBC agglutination technique was more sen-
sitive than the gel technique in detecting the c marker
when a mouse monoclonal antibody was used. In pre-
pared group A, c+ and group O, c– RBC mixed popula-
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Table 1. Grading guide for agglutination reactions
Grade Tube Technique GEL Technique
4+ Solid agglutinate Agglutination band at
+ clear background top of column
3+ Several large agglutinates + Agglutination restricted
clear background to upper half of column
2+ Dispersed agglutinates + Agglutination dispersed
clear background throughout column
1+ Dispersed agglutinates + Agglutination restricted
cloudy background to lower half of column
W+ Microscopic agglutination only Not applicable
0 No agglutination No agglutination
mf = Microscopic evaluation Macroscopic assessment
mixed field of two distinct RBC of band at top of column
populations + RBC pellet at bottom
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tions, the tube technique detected cells expressing the c
antigen at a concentration of 1 percent; the graded
strength of the agglutination increased with increasing
concentrations of cells expressing c (Table 2). The gel
RBC agglutination technique, however, first detected
cells expressing the c marker at a concentration of 10
percent; the agglutination of the c+ RBCs was graded as
a 4+.The 4+ agglutination remained constant as concen-
tration of RBCs expressing c increased. Only subtle dif-
ferences were apparent in the thickness of the aggluti-
nation band at the top of the gel column (Table 2).
The tube and gel RBC agglutination techniques were
equally sensitive for group A when using a mouse mon-
oclonal antibody. In prepared group A, c+ and group O,
c– RBC mixed populations, the A blood group was
detected at a 10 percent concentration by both the tube
and the gel RBC agglutination techniques (Table 2).
Mixed chimeras were more reliably detected by the
gel than by the tube RBC agglutination technique.The
tube technique required a specific awareness of the
posssibility of a mixed field for the technologist to accu-
rately detect it, whereas the gel technique displayed an
indisputable mixed field when it was present, whether
the technologist was alerted to its potential presence or
not. For example, in a prepared mixture of 10 percent
group A, c+ RBCs with group O, c– RBCs, the gel tech-
nique responded with its strongest grade (4+),while the
tube technique revealed a weaker grade reaction (1+)
(Table 2).
Analysis of the patient’s mixed populations
Both assays were able to detect mixed populations
containing group A, c+ RBCs posttransplantation. The
detection of a mixed field using mouse monoclonal anti-
A test sera occurred on Day 20 with the tube RBC agglu-
tination technique but not until Day 26 with the gel RBC
agglutination technique (Table 3). The detection of a
mixed field using mouse monoclonal anti-c test sera
occurred on Day 14 with the tube RBC agglutination
technique but not until Day 26 with the gel technique
(Table 3). It should be noted, however, that macroscopic
detection of mixed fields by the tube technique did not
appear for either marker until Day 26 (Table 3).
Recipient isohemagglutinin levels were measured to
confirm donor stem cell engraftment. As expected,
before PBSC transplantation, the patient’s serum (geneti-
cally type O) contained both anti-A and anti-B. Anti-A
titers steadily decreased from a level of 64 pretransplan-
tation to 1 by Day 42 posttransplantation. Anti-B titers
decreased at a more gradual rate, from a level of 64 pre-
transplantation to 32 by Day 42 posttransplantation
(Table 3).
These results show that RBC engraftment began on
Day 14. Myeloid cell engraftment also occurred by Day
14,but evidence of platelet engraftment was not present
until Day 26.
As a consequence of the ABO-mismatched transplant
engraftment, the DAT first tested positive with polyspe-
cific anti-IgG,C3d on Day 11 and remained positive
through Day 42, which was the last day tested in this
study (Table 3).When the patient’s chimeric (A/O) RBCs
were eluted,anti-A was detected on Day 11.The strength
of anti-A that was eluted increased in successive weeks
from a grade of w+ on Day 14 to a grade of 2+ on Day
42 (Table 3).
Discussion
The gel RBC agglutination technique is currently
approved by the Food and Drug Administration for
reverse ABO typing,DATs,and indirect antiglobulin tests,
and it is being reviewed by the FDA for forward ABO typ-
ing. Although it has failed to detect several clinically
insignificant antibodies, the gel RBC agglutination tech-
nique has increased sensitivity for some antibodies that
may be missed by traditional tube technology.9,10 It is as
good or better than the tube RBC agglutination tech-
nique for the above tests because of its simplicity, relia-
bility, and practicality.11
We found that both the tube and the gel RBC aggluti-
nation techniques can be used to assess mixed popula-
tions of RBCs. Using monoclonal anti-c, the tube RBC
agglutination technique made earlier detection of mixed
fields possible in both prepared and clinical samples,but
this was contingent on microscopic evaluation.However,
microscopic findings are often subject to interpretation
by the technologist. An analysis of macroscopic tube
RBC agglutination readings revealed c antigen mixed-
field detection at the same time posttransplantation as
the gel RBC agglutination technique.
Table 2. Agglutination grade of mixed-chimeric red blood cells (RBCs) 
prepared in the laboratory
RBC Tube RBC agglutination Gel RBC agglutination
composition technique technique
A,c+/O,c– anti-A anti-c anti-A anti-c
50% 4+mf* 4+mf 4+mf heavy 4+mf heavy
40% 4+mf 4+mf 4+mf heavy 4+mf heavy
30% 4+mf 3+mf 4+ mf moderate 4+mf moderate
20% 4+mf 3+mf 4+mf moderate 4+mf moderate
10% 1+mf 1+mf 4+mf light 4+mf light
1% 0 w+mf 0 0
*Mixed field
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The two techniques were comparable when using ABO
antigens to detect engraftment. As with the c antigen
agglutination reactions, microscopic evaluation of ABO
types by the tube RBC agglutination technique detected
erythroid engraftment earlier than did the gel RBC agglu-
tination technique.Yet a comparison of macroscopic data
alone for both techniques revealed detection of ABO
mixed chimeras at identical times posttransplantation.
Thus, the two techniques demonstrated comparable sen-
sitivity in detecting ABO-mismatched mixed chimeras.
It is interesting to note that the patient’s B isohemag-
glutinin titer decreased slightly despite the transplanta-
tion of stem cells from the A donor (Table 3). This
decrease can be attributed to the conditioning regimen
as well as to the lag time before recipient engraftment of
donor lymphocytes and the subsequent production of
anti-B.
In conclusion, if it is critical to detect the earliest pro-
duction of donor RBCs in a particular patient, the tube
RBC agglutination technique may prove the best choice.
After a major ABO-mismatched allogeneic transplant,
however, we found gel RBC agglutination easier to use
and less susceptible to interpretation discrepancies by
the technologist in the detection of mixed fields.
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